Treatment of 22Rv1 prostate cancer cells with Sema4D or dihydrotestosterone (an AR agonist) resulted in a significant increase in endogenous AR in the nucleus, compared to vehicle control (Supplementary Figure S2). This evidence concerns the gene AR and prostate cancer.